NBIX — NEUROCRINE BIOSCIENCES INC
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2016-01-04.
Performance
Technicals
Others in Healthcare
Measured signals that fired on NBIX
| date | signal | measured base rate |
|---|---|---|
| 2026-08-03 | Fair value gap, bearish structure | -0.45% over 21 days · t = -3.29 · n = 108,591 statistically distinguishable from its control group |
| 2026-06-04 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-05-12 | Breakout to a 52-week high price | -1.00% over 21 days · t = -8.58 · n = 24,386 statistically distinguishable from its control group |
| 2026-05-06 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-04-17 | Bollinger bandwidth breaks out of its own compression structure | -0.63% over 21 days · t = -2.80 · n = 7,196 statistically distinguishable from its control group |
| 2026-03-26 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-08-04 | Onyia Jude Chief Scientific Officer | Gift | 2.4K | 0.00 | 0 |
| 2026-07-29 | Norwalk Leslie V Director | Option exercise 10b5-1 plan | 842 | 139.43 | 117.4K |
| 2026-07-28 | Norwalk Leslie V Director | Open-market sale 10b5-1 plan | 1.2K | 182.01 | 227.5K |
| 2026-07-10 | Delaet Ingrid Chief Regulatory Officer | Open-market sale 10b5-1 plan | 4.4K | 181.02 | 790.5K |
| 2026-07-10 | Delaet Ingrid Chief Regulatory Officer | Option exercise 10b5-1 plan | 4.4K | 106.02 | 463.0K |
| 2026-07-09 | Lippoldt Darin Chief Legal Officer | Open-market sale 10b5-1 plan | 10.0K | 179.60 | 1.8M |
| 2026-07-09 | Delaet Ingrid Chief Regulatory Officer | Open-market sale 10b5-1 plan | 8.4K | 178.72 | 1.5M |
| 2026-07-09 | Delaet Ingrid Chief Regulatory Officer | Option exercise 10b5-1 plan | 8.4K | 103.52 | 873.0K |
| 2026-07-09 | Lippoldt Darin Chief Legal Officer | Option exercise 10b5-1 plan | 10.0K | 81.49 | 814.9K |
| 2026-07-08 | Delaet Ingrid Chief Regulatory Officer | Open-market sale 10b5-1 plan | 2.7K | 178.54 | 488.7K |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| BlackRock, Inc. | 1.8B | 13.4M |
| Dodge & Cox | 719.4M | 5.5M |
| JPMORGAN CHASE & CO | 700.5M | 5.4M |
| AQR CAPITAL MANAGEMENT LLC | 650.7M | 4.9M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 622.6M | 4.7M |
| VANGUARD CAPITAL MANAGEMENT LLC | 594.4M | 4.5M |
| STATE STREET CORP | 573.7M | 4.4M |
| TWO SIGMA INVESTMENTS, LP | 403.2M | 3.1M |
| RENAISSANCE TECHNOLOGIES LLC | 318.7M | 2.4M |
| GEODE CAPITAL MANAGEMENT, LLC | 280.8M | 2.1M |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- 10 Health Care Stocks Whale Activity In Today’s Session · 2026-08-21 · benzinga
- Jim Cramer Says Buy Uber, Calls Rockwell Automation 'One Ugly Chart' but a 'Great Long-Term Situation' · 2026-08-18 · benzinga
- Prader-Willi experts flag safety risks linked to Neurocrine's rare disease drug - Reuters · 2026-08-12 · Reuters
- Why is Neurocrine Biosciences stock sliding today? · 2026-08-12
- Neurocrine slips as safety issues linked to Vykat XR resurface (update) · 2026-08-12
- Neurocrine Biosciences stock falls on Vykat safety concerns · 2026-08-12
Ask the AI about NBIX
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →